| http://www.w3.org/ns/prov#value | - Some of the differences in classification between sites of tumor origin versus the molecular classification were known previously and are being tested prospectively in clinical trials???so, on that level we???re already doing some of this clinical validation work. ???There are some barriers, including cost, because we???re using five technologies [to analyze each cancer cell] instead of one.
|
